# **Interagency Autism Coordinating Committee Meeting**

# National Institutes of Health, Bethesda, Maryland Building 31, Conference Room 6C10

# May 16, 2005

8:30 -	9:00	Continental Breakfast
0.00	<b>/•</b> 00	Committee Di Camast

9:00 – 9:05 Introductions

### 9:05 – 10:20 Matrix Related Activities

# **Matrix Updates**

Thomas Insel, M.D., Director National Institute of Mental Health (NIMH)

Richard Fade, Co-founder James Perrin, MD, Board of Directors Autism Treatment Network (ATN)

Gary Goldstein, M.D., Clinical Scientific Advisor Autism Speaks

#### 10:20 - 10:30 Break

# 10:30 – 11:00 Report from IACC Services Subcommittee Implementation of the Autism Services Roadmap

Merle McPherson, M.D.

Health Resources and Services Administration (HRSA)

# 11:00 – 12:00 A National Data Sharing Resource for Autism Research

Alex Rosenthal / Don Preuss

NIH Center for Information Technology (CIT)

Discussant: Jon Shestack, Cure Autism Now (CAN)

#### 12:00 – 12:30 Research on Environmental Influences in Autism

Cindy Lawler, Ph.D.

National Institute of Environmental Health Sciences (NIEHS)

#### 12:30 - 1:30 Lunch

#### 1:30 – 2:15 Science Update

NIEHS Center for Children's Environmental Health and Disease Prevention Research

Isaac Pessah, Ph.D.

University of California, Davis

# 2:15 – 2:45 Updates on Federal Activities

# **Collaborative Programs of Excellence in Autism (CPEA)**

Alice Kau, Ph.D.

National Institute of Child Health and Human Development (NICHD)

# **Studies to Advance Autism Research and Treatment (STAART) Centers**

Deborah Hirtz, M.D.

National Institute of Neurological Disorders and Stroke (NINDS)

# CDC Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE); other CDC activities

José Cordero, M.D., M.P.H.

Center for Disease Control and Prevention (CDC)

# 2:45 – 3:05 Heterogeneity in Autism, Implications for Clinical Trials

Glenn Mannheim, M.D.

Food and Drug Administration (FDA)

# 3:05 – 3:25 Regulatory Approaches to Behavioral Disease Treatment

Paul Andreason, M.D.

Food and Drug Administration (FDA)

#### 3:25 – 3:40 Break

# 3:40 – 4:15 Open Session for Public Comment

# 4:15 – 4:30 Closing Comments and Future Agenda Items

Next meeting date: November 17, 2005